RxDoctor Payments Data

Herbert Lee, MD

Gastroenterology · Irvine, CANPI 1740206689

Payments from drug & device makers

$82,990in general payments, 2019–2025

Across 194 payments — averaging $427.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$69K
  • Phathom Pharmaceuticals, Inc.$14K
  • Alnylam Pharmaceuticals Inc.$146
  • Takeda Pharmaceuticals U.S.A., Inc.$36
  • AbbVie$34
  • Capsovision, Inc.$32
  • plus $83 from 4 others

What the payments were for

  • Consulting fees$3,6104%
  • Speaking & faculty fees$69,23083%
  • Travel & lodging$5,2226%
  • Food & beverage$4,9286%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,990 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$228,812
Medicare patients
233
Services billed
2,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide59$83,974
VoqueznaVonoprazan Fumarate30$25,242
Dexlansoprazole DrDexlansoprazole50$16,060
VascepaIcosapent Ethyl13$4,533
Pantoprazole Sodium392$2,888
Rabeprazole Sodium48$2,155
Lansoprazole43$1,738
Ursodiol14$1,262
Famotidine87$922
Sucralfate66$850
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl48$657
Clindamycin Phosphate41$380
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl20$282
Losartan Potassium23$247
Amlodipine Besylate23$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$68,536$83,97459 claims
Phathom Pharmaceuticals, Inc.Voquezna$14,123$25,24230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →